

ESMO Preceptorship Programme
Prostate Cancer
Multidisciplinary management, standards of care,
Therapeutic targets and future perspectives

9-10 April 2015, Prague, Czech Republic

CHAIRS

Chair: Alan Horwich, UK
Co-Chair: Gedske Daugaard, DK

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

Thursday, 9 April 2015

09:00-09:15 15'	Opening and Welcome
15'	Welcome from ESMO, objectives and scientific introduction
09:15-10:30 80'	Session 1 Screening, diagnosis and staging
25'	Diagnosis, and impact of pathology and genetic changes on prognosis
20'	Screening, investigations and staging classification
20'	Carcinogenesis, aetiology and familial genetics
15'	Discussion
10.35-10.45	Break
10:45-12:30 105'	Session 2 Localised prostate cancer
20'	Role of radiotherapy
20'	Role of surgery
20'	Active surveillance
3x15'	3 x Clinical cases from participants:

Each 15 min slot for clinical cases comprises 7' case presentation plus 8' Q&A/ panel discussion

12:45-13:45	Lunch
13:45-15:15 90'	Session 3 Advanced prostate cancer
10'	Presentation with lymphadenopathy
10'	Urinary obstruction
20'	Value and role of PSA as a tumor marker of response/relapse
	Debate: This house believes that locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation
10'	Argument For
10'	Argument Against
2x15'	2 x Clinical cases from participants:

Each 15 min slot for clinical cases comprises 7' case presentation plus 8' Q&A/ panel discussion

15:15 – 15:45	Break
---------------	-------

15:45-17:15 90'	Session 4 Initial and second-line hormone therapies
30'	First-line hormone therapy for metastatic disease; role and toxicities
30'	Further hormone therapies incl. Abiraterone and Enzalutamide
2x15'	2 x Clinical cases from participants:

Each 15 min slot comprises 7' case presentation plus 8' Q&A/ panel discussion

19:30-22:00	Dinner
-------------	--------

Friday, 10 April 2015

09.00-10:15 75'	Session 5 Castration refractory prostate cancer
25'	First and second-line chemotherapy
25'	Bone targeting (Bisphosphonates and RANK Ligands)
25'	Isotope therapies

10:15 – 10:30	Coffee break
---------------	--------------

10:30-11:45 75'	Session 6 New drugs and targets, including immunotherapy
30'	Immunotherapy
30'	New targets and drugs in current development
15'	Discussion

11:45-12:30 45'	Session 7 Case presentations & take home messages
2x15'	2 x Clinical cases from participants:
15'	Closing remarks and take-home messages

Each 15 min slot comprises 7' case presentation plus 8' Q&A/ panel discussion

12:30-13:15	Standing lunch and departure
-------------	------------------------------

